Drug Database
Back to search

France· FR:66047342

SKYRIZI 150 mg, solution injectable en stylo prérempli

A risankizumab product containing risankizumab, registered in France by ABBVIE DEUTSCHLAND (ALLEMAGNE), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L04AC18

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedSKYRIZI 150 mg, solution injectable e…ATCL04AC18REGISTER NO.FR:66047342PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about risankizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Risankizumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AC18 (risankizumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search risankizumab products by name

Risankizumab · ATC L04AC18

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of risankizumab costs, country by country.

Normalised to the WHO defined daily dose (1.67 mg), the median price runs from $0.035 in France to $26.21 in Switzerland — a ×755 gap.

  • France: $0.035 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Risankizumab · price per daily dose (1.67 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$26.21
  • FR France$0.035
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
RISANKIZUMAB
Manufacturer
ABBVIE DEUTSCHLAND (ALLEMAGNE)
Country
France (FR)
ATC code
L04AC18
ATC class
Risankizumab
Defined daily dose
1.67 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930228142
    1 seringue(s) préremplie(s) en verre de 1 ml dans stylo pré-rempli
    EUR 2.48

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

75 interactions on record for risankizumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check risankizumab against other medicinesHow interaction checks work

Risankizumab · interactions on record

75 records

  • 27 severe
  • 41 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Risankizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All risankizumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Skyrizi
  • Iceland · Skyrizi
  • Liechtenstein · Skyrizi
  • Norway · Skyrizi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bb145d20-1e9d-4107-a2dc-73328975a321
GET /v1/drugs/bb145d20-1e9d-4107-a2dc-73328975a321?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66047342",
  "date_amm": "2021-05-21",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/19/1361",
  "substance": "RISANKIZUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about risankizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console